Operates a diagnostic testing network with central laboratories and patient collection centres across India. In FY26, it added 14 new labs and over 1,100 collection centres, taking the network wider; revenue for the year was Rs. 2,763 crore, up 12.2% year-on-year. Around 75% of revenue comes from B2C patients and the balance from B2B referrals (doctors, hospitals and institutions). The Swasthfit preventive-health package brand contributed 27% of FY26 revenue, while Sovaaka — an AI-powered premium wellness screening brand — was launched with one centre in January 2026. Tier 3+ cities now account for 39% of revenue, and the company is expanding internationally through a Dubai subsidiary and an 80% stake in Ghana's Sunshine Healthcare. The largest cost line is materials (reagents and consumables) at 19.3% of revenue, followed by employee costs at 18.2% and other operating expenses at 34.1%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. B2C patient testing (75%), Swasthfit preventive healthcare packages (27%), Sovaaka premium wellness, B2B (doctors, hospitals, institutions). Asset-light diagnostic services with a hub-and-spoke lab plus franchisee collection-centre network.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 |
| EBITDA (ex other income) | 561 | 490 | 609 | 696 | 752 |
| margin % | 26.9 | 24.3 | 27.4 | 28.3 | 27.2 |
| Owners' profit | 345 | 239 | 358 | 487 | 505 |
| EPS, as reported (₹) | 41.70 | 28.82 | 43.05 | 58.48 | 30.24 |
| ROE % · ROCE % | 22.7 · 27.3 | 14.2 · 19.9 | 19.2 · 26.9 | 22.3 · 28.0 | 20.1 · 25.7 |
| Debt / equity (x) | 0.22 | 0.14 | 0.04 | 0.00 | 0.00 |
| Cash from operations | 447 | 456 | 535 | 569 | 636 |
| Capex | (94) | (37) | (51) | (44) | (167) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 |
| Profit before tax | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 |
| Net profit | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 171 |
| EPS (₹) | 15.52 | 11.60 | 18.57 | 15.88 | 18.05 | 5.42 | 7.86 | 10.15 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. ◆ | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Dr Lal PathLabs publishes notice on unclaimed share transfer | compliance | minimal | — | — |
| 27 Aug 2026 · Dr Lal PathLabs subsidiary completes 30 percent stake buy in Neuome Technologies | strategic transactions | high | — | — |
| 19 Aug 2026 · Dr Lal PathLabs sets up Uzbekistan subsidiary, takes 70% stake | strategic transactions | medium | — | — |
| 6 Aug 2026 · Allotment of 2,11,050 Equity Shares under ESOP Plan 2022 | capital market events | low | — | — |
| 30 Jul 2026 · Dr Lal PathLabs Q1 FY27: Revenue up 19%, PAT up 27%, Rs 5 interim dividend | investor communications | medium | — | — |
| 26 Jul 2026 · Independent Director Gurinder Singh Kalra completes tenure | management changes | medium | — | — |
| 25 Jul 2026 · 32nd AGM held on July 25, 2026; all 10 resolutions passed | board shareholder meetings | medium | — | — |
| 25 Jul 2026 · Dr. Lal PathLabs holds 32nd AGM, approves INR 4 dividend | board shareholder meetings | medium | — | — |
| 25 Jul 2026 · Newspaper publication of Q1 FY27 financial results | compliance | minimal | — | — |
| 24 Jul 2026 · Audio recording of Q1 FY27 earnings call shared on website | investor communications | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 33.9 |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 45.7 | 23.2 | 20 of 29 | 32% |
| P/B | 12.5 | 2.3 | 22 of 24 | 9% |
| ROCE | 24.8 | 6.1 | 3 of 29 | 93% |
| ROE | 20.1 | 7.3 | 5 of 26 | 84% |
| Debt / Equity | 0.0 | 0.0 | 3 of 26 | 68% |
| EBITDA margin | 35.0 | 25.6 | 5 of 24 | 83% |
| Revenue growth | 19.1 | 20.8 | 14 of 25 | 46% |
| Profit growth | 27.2 | 22.0 | 10 of 25 | 63% |
| Market cap | 31794 | 38 | 1 of 30 | 100% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
